SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SOM - SOMNOMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.24

21 Sep
2021

0.040

OPEN

$2.08

1.82%

HIGH

$2.24

88,651

LOW

$2.08

TARGET
$2.61 16.5% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
SOM: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx N/A - 3.4 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx-1.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx57.3 M
Book Value Per Share xxxxxxxxxxxxxxx40.9
Net Operating Cash Flow xxxxxxxxxxxxxxx5.2 M
Net Profit Margin xxxxxxxxxxxxxxx-0.76 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201520162017201820192020
Return on Assets xxxxxxxxxxxxxxx-0.91 %
Return on Equity xxxxxxxxxxxxxxx-1.70 %
Return on Total Capital xxxxxxxxxxxxxxx-2.66 %
Capex xxxxxxxxxxxxxxx2.2 M
Capex % of Sales xxxxxxxxxxxxxxx3.81 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.4 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

25/08/2021

3

Hold

$2.61

16.52%

The FY21 result was a miss on Morgans sales forecasts though stronger product margins aided an in-line underlying earnings (EBITDA) result. The Hold rating is unchanged and the target rises to $2.61 from $2.55.

Guidance is for greater than 15% sales growth (covid withstanding) and a focus on the delivery of a new technology piece at cost of around -$8m in FY22. The latter is considered a potential catalyst by the analyst.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -3.40 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of 2.60 cents.

SOM STOCK CHART